PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has secured a contract to supply LaNeo MDMA to a clinical trial at Harvard’s Maclean Hospital, aiming to improve patient lives by providing high-quality MDMA to U.S. researchers. The company also plans to attend the CPHI Conference in Milan to discuss potential distribution partnerships in Europe.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
